Recent News

• 09.09.2025 - Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
• 09.09.2025 - Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
• 09.02.2025 - Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
• 09.02.2025 - Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
• 08.26.2025 - Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
• 08.26.2025 - Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
• 08.20.2025 - Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
• 08.20.2025 - Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
• 08.12.2025 - Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
• 08.12.2025 - Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Recent Filings

• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.28.2025 - 8-K Current report
• 07.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.23.2025 - EFFECT Notice of Effectiveness